Company Arcturus Therapeutics Ltd Nasdaq
Equities
IL0011280240
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Nucleic Acid-focused Technology
100.0
%
| 206 | 100.0 % | 167 | 100.0 % | -19.03% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 206 | 100.0 % | 167 | 100.0 % | -19.03% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Joseph Payne
CEO | Chief Executive Officer | 52 | 13-02-28 |
Andrew Sassine
DFI | Director of Finance/CFO | 59 | 18-12-31 |
Chief Operating Officer | 45 | 12-12-31 | |
Chief Tech/Sci/R&D Officer | 68 | 23-02-28 | |
Neda Safarzadeh
IRC | Investor Relations Contact | - | - |
Lance Kurata
LAW | General Counsel | 54 | 20-08-09 |
Kevin T. Skol
PRN | Corporate Officer/Principal | - | 01-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Edward W. Holmes
BRD | Director/Board Member | 83 | 19-08-31 |
James F. Barlow
BRD | Director/Board Member | 65 | 18-05-26 |
Peter Farrell
CHM | Chairman | 81 | 18-05-26 |
Andrew Sassine
DFI | Director of Finance/CFO | 59 | 18-12-31 |
Magda Marquet
BRD | Director/Board Member | 65 | 18-05-26 |
Jing Marantz
BRD | Director/Board Member | 59 | 21-12-06 |
Joseph Payne
CEO | Chief Executive Officer | 52 | 13-02-28 |
John Markels
BRD | Director/Board Member | 58 | 22-12-07 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 26,931,826 | 24,577,248 ( 91.26 %) | 0 | 91.26 % |
Company contact information
Arcturus Therapeutics Holdings, Inc.
10628 Science Center Drive Suite 250
92121, San Diego
+
http://www.arcturusrx.comSector
1st Jan change | Capi. | |
---|---|---|
+33.37% | 49.46B | |
+1.55% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.57% | 26.61B | |
-21.00% | 18.64B | |
+7.36% | 13.16B | |
+28.30% | 12.55B | |
+23.80% | 12.1B |